Danna (Tianjin) Biotechnology Co., Ltd. received a research visit from several institutions including Kaiyuan Securities, Xinhua Fund, Jianxin Pension, Guolian Fund, Wukuang Trust, Yizhi Investment, Huatai Bosheng Fund, CITIC Securities, Qingchuang Bole, Guideline Fund, Hongta Securities, Zhongtai Securities, Changjiang Securities, Chengying Investment, and Qingdao Luxiu Investment at the Westin Hotel in Beijing's Financial Street on May 21. Mr. Li Haoyi, the company's board secretary, participated in this reception activity.
Regarding the application scenarios and market development stages of invasive fungal disease serological testing, the company stated in response: &#34;Invasive fungal disease is a severe infection caused by pathogenic or opportunistic fungi such as Candida, Aspergillus, and Cryptococcus invading tissues or the bloodstream, commonly occurring in patients with hematological diseases/malignancies, hematopoietic stem cell transplants, solid organ transplants, intensive care units, AIDS, and those on long-term corticosteroids, broad-spectrum antibiotics, and immunosuppressants. Invasive fungal disease is characterized by 'three highs and one difficulty,' namely high incidence, high mortality, high missed diagnosis rate, and difficulty in clinical diagnosis.&#34; &#34;Fungal serological biomarker testing has advantages such as being non-invasive, rapid, highly sensitive, and capable of dynamic monitoring, allowing for the early detection of pathogen-related signals and compensating for the shortcomings of traditional methods. The main application scenarios are in the laboratory departments of medical institutions and third-party medical testing laboratories.&#34; &#34;Currently, the domestic invasive fungal testing market is still in the stages of market education and development, with insufficient clinical awareness in this field. Invasive fungal testing requires a high level of disease awareness and diagnostic capability from clinical doctors, and the project implementation rate in secondary hospitals is relatively low. However, with the accelerated construction of industry guideline consensus and collaborative promotion by institutions such as fungal disease monitoring networks, the clinical awareness and diagnostic capabilities of secondary hospitals are expected to continue to improve. The current development path of fungal testing has gradually extended from accurately identifying infecting fungal species to precise diagnosis + medication guidance, enabling the detection of fungal drug resistance, matching better treatment drugs, reducing the misuse of antimicrobial drugs, and lowering the medical burden on patients.&#34;
Regarding the impact of the national medical service pricing project guidelines for testing on the company, the company stated: &#34;Currently, the national medical service pricing project guidelines for testing have completed the solicitation of opinions phase. The guidelines focus on covering high clinical value areas such as tumor marker testing, molecular pathology testing, and infectious disease testing, guiding resources towards high-value, high-clinical-demand testing projects by standardizing the pricing and charging of these projects. The company has several fungal testing products included in the scope of the testing medical service pricing project guidelines (draft for solicitation of opinions).&#34;
Regarding the future key business development direction, the company disclosed: &#34;The company's future business development will adopt a strategy of coordinating advancement along two main lines: product and market. On the product side, the company will focus on the iterative upgrade of precise diagnostic technologies and products. Existing products already possess the capability for diagnosing invasive fungal infections and identifying common pathogenic fungal species. By 2025, the company successfully obtained registration certificates for two molecular diagnostic products; by 2026, it will focus on promoting the registration and certification of more molecular diagnostic products. Based on the identification of Candida and Aspergillus, molecular diagnostic products can further accurately distinguish specific species such as Eurotium, Aspergillus flavus, Aspergillus niger, and Aspergillus terreus, significantly improving diagnostic accuracy
In addition, drug resistance testing products are an important component of the company's layout in precision medicine and a key focus for certification work in 2026. On the market side, the company will continue to deepen its domestic market efforts while strengthening market education, and expanding into overseas markets as an important strategic direction. In 2025, the company's overseas revenue was 10.9479 million yuan, accounting for 4.52% of total revenue, with significant growth potential. The overseas market will be one of the core focus points for the company's business expansion in the future.
Regarding the market space for drug resistance testing products, the company stated: &#34;The drug resistance testing products developed by the company will greatly shorten the testing cycle and enable rapid issuance of drug sensitivity reports. The treatment of fungal infections requires high timeliness, and rapid and accurate drug resistance testing helps clinicians quickly identify suitable drug regimens, winning valuable treatment time for patients, which has significant clinical value and market prospects.&#34;
On the supply issues of horseshoe crab blood raw materials and the promotion plan for non-horseshoe crab blood-dependent testing products, the company stated: &#34;To address the supply of horseshoe crab blood raw materials, the company has implemented two major assurance measures: First, it has established a stable channel for importing horseshoe crab blood cells from Vietnam, and the company currently has sufficient inventory of horseshoe crab blood cells; second, the company has developed G test products that do not require horseshoe crab blood and do not rely on artificially synthesized factors. Relevant products have obtained registration certificates and meet clinical testing requirements in terms of specificity and sensitivity, demonstrating good substitution capability.&#34; &#34;In terms of market promotion strategy, the company's existing horseshoe crab blood raw material testing reagent products have accumulated a high level of familiarity and product recognition among end customers over more than a decade of clinical experience. Based on this, the company adopts a prudent promotion strategy for existing G test product customers and has not actively promoted substitute products on a large scale, only targeting a few customers with clear needs for directed promotion. For new customers who have not yet conducted G tests, the company will comprehensively assess their sample size, automation needs, and other practical situations to actively promote the hospital access work for relevant substitute products.&#34;
Regarding the establishment of DanChong Bio to layout pet pathogen microorganism testing, the company stated: &#34;The company has established DanChong Bio to focus on the pet pathogen microorganism testing track, which has a large market space and is an extension of the company's business in the diagnostic field. Currently, it has laid out rapid testing products for various common epidemic pathogens, including canine distemper, canine parvovirus, canine infectious hepatitis, feline panleukopenia, feline calicivirus infection, feline infectious peritonitis, and leishmaniasis.&#34;
According to Changbi Finance, the company is a national high-tech enterprise focused on the early diagnosis of invasive fungal diseases and other pathogen microorganism in vitro diagnostic products, recognized as one of the first batch of key specialized and innovative &#34;little giant&#34; enterprises supported by the state, a single champion enterprise in Tianjin's manufacturing industry, a national intellectual property advantage enterprise, one of the first batch of Cheetah enterprises in Tianjin, winner of Tianjin Patent Gold Award, and recipient of the First Prize for Scientific and Technological Progress from the Central Military Commission, among other honors

Dana Biosciences hosted multiple institutional research meetings in Beijing on May 21 to discuss the market status and strategic layout of invasive fungal diseases. The company pointed out that invasive fungal diseases have a high incidence and mortality rate, and fungal serological testing has advantages in early diagnosis. Although the domestic market is still in the education and development stage, with the advancement of industry guidelines, the awareness and diagnostic capabilities of secondary hospitals are expected to improve

同壁财经

CITIC Securities Co., Ltd.

CITIC SEC

Hongta Securities

ZHONGTAI SECURITIES

Changjiang Securities

Danna Biotechnology (920009) disclosed the record of investor relations activities, detailing the current status and strategic layout of the fungal testing market